Effects of cerivastatin withdrawal on statin persistence

Annals of Pharmacotherapy

Volumn 42, Issue 7-8, 2008, Pages 956-961

  Reaume, Kristen T ^a   Erickson, Steven R ^a,b   Dorsch, Michael P ^a   Dunham, Niquole L M ^c   Hiniker, Susan M ^a   Prabhakar, Nitya ^a   Kline Rogers, Eva M ^a   Eagle, Kim A ^a,d  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^d Department of Internal Medicine ^*

Author keywords

Acute coronary syndrome; Drug recall; Persistence; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; DECISION MAKING; DRUG MARKETING; EVALUATION; FEMALE; HEALTH SURVEY; HUMAN; KRUSKAL WALLIS TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANK SUM TEST; REGISTER; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

ACUTE CORONARY SYNDROME; AGED; ANALYSIS OF VARIANCE; DRUG AND NARCOTIC CONTROL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MASS MEDIA; MICHIGAN; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT DROPOUTS; PRODUCT SURVEILLANCE, POSTMARKETING; PYRIDINES; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 48249138053     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K575     Document Type: Article

References (23)

1. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). 2002. www.acc.org/clinical/guiderines/ unstable/unstable.pdf (accessed 2006 Jul 28).
2. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115:e69-171.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
4. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events trial investigators. N Engl J Med 1996;335:1001-9.
5. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
6. Schwartz GG, Olsson AG, Ezekowitz MD, et al., for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-8.
7. Eagle KA, Mehta RH, Riba AL, et al. Taking the ACC/AHA guidelines for care of acute myocardial infarction to the bedside: the GAP projects in southeastern Michigan. Am Heart J 2004;148(suppl 1):S49-51.
8. Eagle KA, Kline-Rogers E, Goodman SG, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med 2004;117:73-81.
9. Eagle KA, Montoye CK, Riba AL, et al. Guideline-based standardized care is associated with substantially lower mortality in Medicare patients with acute myocardial infarction. The American College of Cardiology's Guidelines Applied in Practice (GAP) projects in Michigan. J Am Coll Cardiol 2005;46:1242-8.
10. Sung JC, Nichol MB, Venturini F, Bailey KL, McCombs JS, Cody M. Factors affecting patient compliance with antihyperlipidemic medications in an HMO population. Am J Manag Care 1998;4:1421-30.
11. Sud A, Kline-Rogers EM, Eagle KA, et al. Adherence to medications by patients after acute coronary syndromes. Ann Pharmacother 2005;39:1792-7. Epub 4 Oct 2005. DOI 10.1345/aph.1G249
12. Berg JS, Dischler J, Wagner DJ, Raia JJ, Palmer-Shevlin N. Medication compliance: a healthcare problem. Ann Pharmacother 1993;27:S1-24.
13. Rosenstock IM, Strecher VJ, Becker MH. Social learning theory and the health belief model. Health Educ Q 1988;15:175-83.
14. Mirotznik J, Feldman L, Stein R. The health belief model and adherence with a community center-based, supervised coronary heart disease exercise program. J Commun Health 1995;20:233-47.
15. Smith DL. DTC ads: promoting compliance a win-win prospect. Pharmaceutical Executive 1999;19:84-5.
16. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-61.
17. Heeschen C, Hamm CW, Laufs U, et al., for the Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002;105:1446-52.
18. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med 2005;165:1363-9.
19. Cawley J, Rizzo JA. The competitive effects of prescription drug withdrawals. Presented at: Indiana University Microeconomics Workshop. www.indiana.edu/~econdept/workshops/Cawleypaper.pdf (accessed 2006 Jul 28).
20. FDA Talk Paper: Bayer voluntarily withdraws Baycol. www.fda.gov/bbs/ topics/ANSWERS/2001?ANS01095.html (accessed 2006 Jul 28).
21. Bayer pulls key drug. http://cnn.com (accessed 2006 Jul 28).
22. Sales of cholesterol drug halted. St. Petersburg Times Online World and Nation. 2001. www.sptimes.com (accessed 2006 Jul 28).
23. Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med 1997;241:317-25.